Table of Contents

Volume 113, Issue S1 (S1-S21)
Published 15 December 2015

PARP inhibitors in ovarian cancer

Organizer: AstraZeneca UK

Guest Editor: Jonathan A Ledermann

In this supplement, the authors comprehensively review molecular and clinical evidence underlying the evolution of poly (ADP-ribose) polymerase (PARP) inhibitors in a journey spanning 50 years, which culminates in the recent licensing approval of the first oral PARP inhibitor, olaparib (Lynparzat™), for BRCA-mutated high-grade serous ovarian cancer. In addition, it discusses current UK procedures for BRCA testing of at-risk women and considers BRCA mutation genetic testing models for patients with ovarian cancer.

Disclosure

Medical writing support was provided by Mudskipper and Nyxeon and funded by AstraZeneca.

Top

Foreword

PARP inhibitors in ovarian cancer FREE

David Cibula and Judith Balmaña

Br J Cancer 113: S1-S2; doi:10.1038/bjc.2015.392

Top

Minireviews

The development of PARP inhibitors in ovarian cancer: from bench to bedside FREE

Yvette Drew

Br J Cancer 113: S3-S9; doi:10.1038/bjc.2015.394

PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions FREE

Jonathan A Ledermann and Fatima El-Khouly

Br J Cancer 113: S10-S16; doi:10.1038/bjc.2015.395

UK BRCA mutation testing in patients with ovarian cancer FREE

Angela George

Br J Cancer 113: S17-S21; doi:10.1038/bjc.2015.396